U.S. markets open in 8 hours 55 minutes

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.39+4.19 (+12.25%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close34.20
Open34.39
Bid0.00 x 1000
Ask0.00 x 1400
Day's Range33.35 - 40.00
52 Week Range22.51 - 47.29
Volume2,146,574
Avg. Volume995,907
Market Cap1.336B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.32
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      UPDATE - Trends in Psychedelic Drugs Research and Four Stocks You Should Know About

      OTCStockReview.com News CommentaryATLANTA, Oct. 16, 2020 (GLOBE NEWSWIRE) -- 2020 has been quite a year, but hidden among the carnage is great news about advances in research on psychedelic medicine to treat mental health issues. In January Johns Hopkins announced it had launched the Center for Psychedelic and Consciousness Research three months earlier. With $17 million in private funding and a full panel of planned studies, Johns Hopkins' researchers planned to focus on how psychedelics impact brain function and mood in both healthy individuals and those affected by mental health issues. What John Hopkins did not realize is that it would be sparking the psychedelic revolution. Psychedelics, like psilocybin, are garnering interest from mainstream America. Denver, Oakland, and Santa Cruz have recently legalized its use. Ann Arbor, Michigan lawmakers voted to decriminalize psilocybin mushrooms and a ballot in Oregon could legalize its use by November 2020. This paradigm-shift in the treatment of mental health disorders could be the single best thing to come out of 2020. As researchers and the medical community develop more valuable tools for understanding the brain’s connection to mind and behavior, millions of people all over the world will benefit. Numerous studies on psychedelics are already proving such treatments can treat a host of mental issues, like obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. As clinical trials supporting psychedelic treatments begin to prove the theories of researchers, we would expect to see big pharmaceutical companies investing heavily into psychedelics for their own drug pipelines.In our opinion, this opens up significant opportunities for investors to profit from psychedelic stocks in the coming months. A few companies to put on your radar screen are COMPASS Pathways (NASDAQ:CMPS), Mind Medicine Inc. (OTC: MMEDF), Ehave, Inc. (OTC: EHVVF), and Revive Therapeutics Ltd. (OTC Pink: RVVTF).COMPASS Pathways (NASDAQ:CMPS) came public on the NASDAQ at $17.00 a share on September 18th, 2020, making it the first psychedelic company to be listed on a U.S. exchange. Since then, CMPS shares have traded as much as 160% above the offering price, providing investors with a tremendous short-term return. CMPS did more than provide investors with a huge return; it also alerted a whole new crop of investors to psychedelic medicine stocks. Co-founded by George Goldsmith and Ekaterina Malievskaia, COMPASS Pathways added Lars Christian Wilde and went to work developing psilocybin (the active compound in magic mushrooms) for use in patients with treatment-resistant depression. COMPASS Pathways is currently conducting an FDA phase IIb clinical trial of psilocybin therapy for treatment resistant depression in 20 sites across Europe and North America. The Company expects to have results in 2021.COMPASS Pathways is based in London, UK and the Company is pioneering the development of a new model of psilocybin therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA) for treatment-resistant depression (TRD). H.C. Wainwright analyst Patrick Trucchio initiated coverage on COMPASS Pathways October 14, 2020 with a Buy rating and set a price target of $65.00. Canaccord Genuity also initiated coverage with a Buy rating on the stock with an $80.00 price target. www.compasspathways.comEhave, Inc., (OTC Pink: EHVVF) is making its mark in the psychedelic medicine space as a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Ehave's proprietary Dashboard utilizes BlockChain technology to provide better communication among health care providers for better patient outcomes and is compliant with both HIPAA and GDPR standards. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. With an interest in psychedelic research, Ehave's Dashboard offers the medical and research community an opportunity to share information with an emphasis on security. The Ehave Dashboard has been developed through years of testing with mental healthcare professionals at one of Canada’s largest hospitals, Toronto’s Hospital for Sick Children. In addition to providing better outcomes, the proprietary platform allows individuals to take control of their physical and mental health by enabling them to carry their medical records with them wherever they go.Ehave also owns a piece of the PsyTech Summit , which brings together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. As a result of the Covid-19 pandemic, the PsyTech Summits are being held virtually, but still cater to thousands of virtual attendees, as well as live guests at select city hubs across four continents.  PsyTech Summit 2020 will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Register free at https://www.psytech.biz. Speakers for the conference include Dr. Julie Holland who is a psychiatrist, psychopharmacologist, and author of the New York Times bestseller Moody Bitches and Weekends at Bellevue; David Nutt who is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Hammersmith Hospital, Imperial College London; Dr. Beatriz Caiuby Labate (Bia Labate) who is the Executive Director of the Chacruna Institute for Psychedelic Plant Medicines; Rick Doblin, Ph.D. who is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS); and Del Joly former business development for Charlotte’s Web. www.ehave.comMind Medicine (OTCQB: MMEDF) made the last big splash in the psychedelic medicine pool. The Company raised $24 Million in a pre IPO round which included Kevin O’Leary and Bruce Linton, a founder of Canopy Growth Corporation. Since coming public the stock has more than doubled. Mindmed listed in March on the Canadian NEO exchange and here in the US on the Other OTC. The shares now trade on the OTCQB. Since then MindMed has moved beyond ketamine and psilocybin mushrooms and now looking towards LSD (lysergic acid diethylamide) as a treatment compound. MindMed has started clinical trials for LSD to treat anxiety and cluster headaches, as well as clinical trials for MDMA (3,4 Methylenedioxymethamphetamine) and DMT (the active ingredient in Ayahuasca). The company is planning to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. MindMed applied for an up-listing on the NASDAQ on September 21, 2002, just days after Compass Pathways went public.On October 9, 2020 MindMed announced a $25 million bought deal public offering. The press release announcing the capital raise was not supposed to be released in the U. S., but since the OTCQB symbol is in there, it was hard to miss. A bought deal is a securities offering usually done in Canada in which an investment bank assumes the risk of committing to buy the entire offering from the client company. Canaccord Genuity Corp. acted as the lead underwriter, and Canaccord Genuity Corp. analyst Tania Gonsalves said in a recent report that psychedelic medicines and psychedelic-assisted therapy could become a $100 billion market. www.mindmed.coRevive Therapeutics Ltd. (OTC Pink: RVVTF) is an Ontario, Canada based life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.In February, RVVTF announced plans to acquire Psilocin Pharma Corp. for $2.75 million. Psilocin has developed production solutions for the active compound Psilocybin. The precisely dosed formulations work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to eventually Food and Drug Administration approval in the treatment of conditions such as depression, anxiety, bi-polar disorder, bulimia and anorexia. The company also filed an IND for a COVID treatment. www.revivethera.comDISCLAIMER: OTC Stock Review (OTCSR), which owns and operates OTCStockReview.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. OTCSR is NOT affiliated in any manner with any company mentioned herein. OTCSR and its affiliated companies is a news dissemination solutions provider and are not a registered broker/dealer/analyst/adviser. OTCSR holds no investment licenses and may not sell, offer to sell or offer to buy any security. OTCSR's market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. OTCSR is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed OTCSR was compensated one thousand five hundred dollars for news coverage of current press releases issued by Ehave, Inc. by a non-affiliated third party. OTCSR HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCSR undertakes no obligation to update such statements.Contact Information:David Kugelman(404) 856-9157 Office(866) 692-6847 Toll Free - U.S. & Canadadk@otcstockreview.comhttps://www.linkedin.com/in/davidkugelman

    • COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
      GlobeNewswire

      COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares

      COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary SharesLondon, UK – September 22, 2020COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the closing of its previously announced initial public offering of 8,625,000 American Depositary Shares (“ADSs”) representing 8,625,000 ordinary shares at an initial public offering price of $17.00 per ADS, which includes 1,125,000 additional ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs. The total gross proceeds to COMPASS from the offering were $146.6 million. All ADSs sold in the offering were offered by COMPASS. The ADSs began trading on the Nasdaq Global Select Market on September 18, 2020 under the ticker symbol “CMPS.”  Cowen, Evercore ISI and Berenberg are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.A registration statement relating to these securities has been filed with the US Securities and Exchange Commission (the “SEC”) and was declared effective on September 17, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, telephone: (888) 474-0200, or email: ecm.prospectus@evercore.com; or Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, New York 10020, or by telephone at +1 (646) 949-9000, or by e-mail at prospectusrequests@berenberg-us.com. For the avoidance of doubt, such prospectus will not constitute a “prospectus” for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and will not have been reviewed by any competent authority in any EU member state or the UK.This press release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.For readers in the European Economic Area (“EEA”) and the UK In any EEA member state and the UK (each, a “Relevant State”), this press release and any offering are only addressed to and directed at persons who are qualified investors ("Qualified Investors") in that Relevant State within the meaning of the Prospectus Regulation. The term “Prospectus Regulation” means Regulation (EU) 2017/1129.For readers in the UK In the UK, this press release, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended (the “FSMA”), and any offering are only addressed to and directed at Qualified Investors (i) who are investment professionals as described in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) persons and entities who fall within Article 49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as “relevant persons”).This press release must not be acted on or relied on (i) in the UK, by persons who are not relevant persons, and (ii) in any EEA member state, by persons who are not Qualified Investors. Any investment or investment activity to which this press release relates is available only to and will only be engaged with (i) in the UK, relevant persons, and (ii) in any EEA member state, Qualified Investors. This press release does not contain an offer or constitute any part of an offer to the public within the meaning of sections 85 and 102B of the FSMA or otherwise.About COMPASS Pathways COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.Enquiries: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024 Amy Lawrence, amy@compasspathways.com, +44 7813 777919

    • First Psychedelic Drug Stock Hits $1 Billion In Debut After Upsized IPO
      Investor's Business Daily

      First Psychedelic Drug Stock Hits $1 Billion In Debut After Upsized IPO

      Compass Pathways jumped in its first day of trading on Friday, making it the first psychedelic drug company to go public on a big U.S. exchange.